Loading...

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

BACKGROUND: Combined inhibition of epidermal growth factor receptor (EGFR) and Src family kinases (SFK) may lead to improved therapeutic effects. We evaluated the combination of dasatinib, an inhibitor of SFK and other kinases, and cetuximab, an anti-EGFR monoclonal antibody. PATIENTS AND METHODS: P...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Argiris, Athanassios, Feinstein, Trevor M., Wang, Lin, Yang, Tianbing, Agrawal, Shruti, Appleman, Leonard J., Stoller, Ronald G., Grandis, Jennifer R., Egloff, Ann Marie
Format: Artigo
Sprog:Inglês
Udgivet: 2011
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3402509/
https://ncbi.nlm.nih.gov/pubmed/21881918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9732-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!